Herb-Drug Interactions

草药 - 药物相互作用
  • 文章类型: Journal Article
    心血管疾病(CVD)是全球范围内导致死亡的主要原因之一,其内科治疗大多是单一/少数目标化学药物。长期使用心血管药物治疗复杂的慢性疾病可能导致严重的药物不良反应。中医药治疗心脏病已有数千年的历史,有助于缓解症状,延长患者的寿命。中药具有多成分的药理特点,多靶点、多途径,中西医结合可作为治疗慢性、疑难杂症的替代治疗方法,安全性较高。本文综述了中药与心血管药物的相互作用和协同作用。在心律失常的治疗中,中西医结合能更有效地调节患者的心脏电生理特点,减少早搏和心率变异性的发作,降低QT间期离散度和血清炎症因子水平,减轻临床症状和中医证候,并以良好的安全水平改善心脏功能。在高血压的治疗中,能更稳定地降低血压和血清炎症因子水平,改善血流动力学指标和运动耐量,它具有很高的安全级别,尤其是孕妇。至于冠心病,中药和抗血小板药物的联合使用可能会促进彼此的吸收。然而,在疗效剂量下,它们之间的药代动力学机制的相互作用风险较低。中西医结合可降低N末端脑钠肽前体水平,安全性较高的心力衰竭患者可以延缓心脏重构,改善心功能和生活质量。
    Cardiovascular disease (CVD) is one of the leading causes of death worldwide, and its internal medicine treatments are mostly single/few-target chemical drugs. Long-term use of cardiovascular drugs for complex chronic diseases may lead to serious adverse drug reactions. Traditional Chinese medicine (TCM) has been used to treat heart diseases for thousands of years, helping to ease symptoms and prolong patients\' lifespan in ancient China. TCM has the pharmacological characteristics of being multi-component, multi-target and multi-pathway, and the combined application of TCM and western medicine can be an alternative treatment for chronic and intractable diseases with high safety levels. This article reviewed the interactions and synergistic effect of TCM and cardiovascular drugs. In the treatment of arrhythmia, TCM combined with western medicine can more effectively regulate patients\' cardiac electrophysiological characteristics, reduce the onsets of premature beat and heart rate variability, lower the levels of QT interval dispersion and serum inflammatory factors, alleviate clinical symptoms and TCM syndromes, and improve cardiac function with good safety levels. In the treatment of hypertension, integrative medicine can more steadily reduce blood pressure and levels of serum inflammatory factors and improve hemodynamic indexes and exercise tolerance, and it has high safety levels, especially for pregnant women. As for coronary heart disease, the combination of TCM and antiplatelet drugs may promote the absorption of each other. However, the interaction risk of pharmacokinetic mechanism between them is low at the dose of efficacy. Integrative medicine can reduce the level of N-terminal pro-brain natriuretic peptide, delay cardiac remodeling and improve heart function and quality of life for patients with heart failure with high safety levels.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    联合治疗与2型糖尿病(T2DM)患者的药物相互作用(DDI)风险增加相关。本研究旨在调查潜在DDI(PDDI)的流行病学,包括潜在的化学药物相互作用(pCDIs)和潜在的草药-药物相互作用(pHDIs),并对这些患者pDDIs的影响因素进行分类。
    在2019年的12个月期间,对18岁以上的T2DM住院患者中pDDIs的流行病学进行了回顾性研究。用C(监测治疗)鉴定PDDI,D(考虑治疗修改),和X(避免组合)风险评级。采用二元Logistic回归分析pDDI的危险因素。
    在住院期间,共从737名T2DM住院患者中发现6796名pDDIs,0.87%被列为X风险评级,13.39%为D级风险评级。此外,1753pDDIs在出院后被确认,0.11%为X,25.73%为D风险评级。药物-药物关联网络显示大多数pCDI与心血管系统药物相关。氯苯那敏-氯化钾和丹参-华法林是住院期间最普遍的pCDIs和pHDIs相互作用对,评分为X。多变量分析表明,在接受超过8种药物治疗的T2DM患者中,发生超过4pDDI的可能性明显更高。出院后pDDIs的存在与T2DM的并发症和出院药物的数量密切相关。
    T2DM患者经常暴露于pDDIs,包括pCDI和pHDI,住院期间和出院后。多药联合用药是pDDIs的主要危险因素。加强对DDI的监测和预警等策略,增加临床药理经验,以及制定普遍适用的pDDIs临床指南可能有助于降低潜在有害药物组合的发生率。
    UNASSIGNED: Combination therapy was associated with an increased risk of drug- drug interactions (DDIs) in patients with type 2 diabetes mellitus (T2DM). The present study aimed to investigate the epidemiology of potential DDIs (pDDIs), including potential chemical drug-drug interactions (pCDIs) and potential herb-drug interactions (pHDIs), and classify the influencing factors of pDDIs in these patients.
    UNASSIGNED: A retrospective study of the epidemiology of pDDIs among T2DM hospitalized patients older than 18 years and treated with at least two drugs during hospitalization was conducted over a 12-month period in 2019. PDDIs were identified with C (monitor therapy), D (consider therapy modification), and X (avoid combination) risk ratings. Binary logistic regression was used to analyze the risk factors of pDDIs.
    UNASSIGNED: A total of 6796 pDDIs were identified from 737 T2DM hospitalized patients during hospitalization, with 0.87% classified as X risk rating, 13.39% as D risk rating. Additionally, 1753 pDDIs were identified after discharge, with 0.11% as X and 25.73% as D risk rating. The drug-drug association networks showed that the majority of pCDIs were associated with cardiovascular system drugs. Chlorphenamine-potassium chloride and danshen-warfarin were the most prevalent interacting pairs of pCDIs and pHDIs with X rating during hospitalization. Multivariate analysis indicated that the likelihood of developing over 4 pDDIs was significantly higher among T2DM patients who had received over 8 medications. The presence of pDDIs after discharge was strongly associated with the complications of T2DM and the number of discharge medications.
    UNASSIGNED: T2DM patients were frequently exposed to pDDIs, including pCDIs and pHDIs, both during hospitalization and after discharge. Multi-drug combination was the primary risk factor for pDDIs. Strategies such as enhancing the monitoring and warning for pDDIs, increasing clinical pharmacological experience, as well as developing universally applicable clinical guidelines for pDDIs may be beneficial in reducing the incidence of potentially harmful drug-combinations.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    对乙酰氨基酚(APAP),或者扑热息痛,是世界上最广泛和最常用的非处方止痛药之一,并能有效控制广泛的疼痛,包括头痛,肌肉疼痛,和轻微的关节炎疼痛。虽然人们普遍理解APAP的药代动力学,缺乏有关其转移比率的数据,尤其是进入膝盖的数据。开发了一种新颖的多微透析模型,可以同时从血液中采样,前肢伸肌,脑纹状体,和同一实验对象的膝关节腔,以研究APAP与牛膝之间的潜在相互作用(A.bidentata),另一种广泛使用的中草药,特别用于下肢疼痛。用A.bidentata提取物(ABex)对大鼠进行预处理,然后施用APAP(60mg/kg,i.v.),随后使用HPLC-PDA分析透析液。我们的分析表明APAP浓度,单独或与ABEX联合给药后达到(1和3g/kg,q.d.灌胃),可以用一室模型有效地建模。血液与肌肉的分配比(AUCorgan/AUCpblood),给予APAP后,血对脑和血对膝分别为0.372±0.053,0.277±0.095和0.191±0.042(60mg/kg,i.v.).APAP单独给药和与ABex联合给药的药代动力学之间没有观察到显着差异;在所有采样器官中,APAP浓度超过最大有效浓度(EC50)的一半,持续近3小时,为其广泛的镇痛作用提供证据。
    Acetaminophen (APAP), or paracetamol, is one of the most widespread and commonly used non-prescription pain medication in the world, and is effective at managing wide range of pain, including headache, muscle ache, and minor arthritic pain. While the pharmacokinetics of APAP is generally understood, there is a lack of data for its transfer ratio especially into the knee. A novel multi-microdialysis model was developed to simultaneously sample from blood, forelimb extensor muscle, brain striatum, and the knee joint cavity in the same experimental subject to investigate the potential interaction between APAP and Achyranthes bidentata Blume (A. bidentata), another widely used traditional Chinese medicininal herb especially for pain in the lower extremity. Rats were pre-treated with A. bidentata extract (ABex), APAP was then administered (60 mg/kg, i.v.), dialysates then subsequently analyzed using HPLC-PDA. Our analysis demonstrated that APAP concentrations, achieved after its administration either alone or in combination with ABex (1 and 3 g/kg, q.d. gavage), could be modelled effectively with a one-compartment model. The distribution ratio (AUCorgan/AUCblood) of blood-to-muscle, blood-to-brain and blood-to-knee was 0.372 ± 0.053, 0.277 ± 0.095 and 0.191 ± 0.042, respectively after administration of APAP (60 mg/kg, i.v.). No significant difference was observed between the pharmacokinetics of APAP administered alone and in combination with ABex; and APAP concentration exceed the half maximal effective concentration (EC50) in all sampled organs for close to 3 hours with one single dose of drug administration, providing evidence for its broad-range analgesic effect.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    多药和毒素挤出蛋白1(MATE1),外排转运体主要在肾近端小管中表达,介导有机阳离子药物的肾脏分泌。抑制MATE1会损害药物向肾小管的排泄,导致肾毒性药物在肾脏中积累,从而增强肾毒性。筛选和鉴定有效的MATE1抑制剂可以预测或最小化药物诱导的肾损伤的风险。黄酮类化合物,在食品和草药产品中常见的一组多酚,已报道引起转运蛋白介导的食物/草药-药物相互作用。我们的目的是研究黄酮类化合物对MATE1的体外和体内抑制作用,并评估黄酮类化合物对顺铂诱导的肾损伤的影响。13种黄酮类化合物在MATE1-MDCK细胞中对MATE1表现出显著的转运活性抑制(>50%)。其中,六种最强的类黄酮抑制剂,包括irisflorentin,水飞蓟素,异飞蓟宾,sinensetin,橘皮素,和诺比林,在这些细胞中显著增加顺铂的细胞毒性。在顺铂诱导的体内肾损伤模型中,irisflorentin,异飞蓟宾,和西能西汀也不同程度地增加了血清肌酐和血尿素氮水平,尤其是irisflorentin,表现出最有效的顺铂肾毒性。药效团模型表明,3、5和7位的氢键受体可能在类黄酮对MATE1的抑制作用中起关键作用。我们的发现为预测含类黄酮的食物/草药-药物相互作用的潜在风险以及避免通过MATE1介导药物引起的肾损伤的恶化提供了有用的信息。
    Multidrug and toxin extrusion protein 1 (MATE1), an efflux transporter mainly expressed in renal proximal tubules, mediates the renal secretion of organic cationic drugs. The inhibition of MATE1 will impair the excretion of drugs into the tubular lumen, leading to the accumulation of nephrotoxic drugs in the kidney and consequently potentiating nephrotoxicity. Screening and identifying potent MATE1 inhibitors can predict or minimize the risk of drug-induced kidney injury. Flavonoids, a group of polyphenols commonly found in foodstuffs and herbal products, have been reported to cause transporter-mediated food/herb-drug interactions. Our objective was to investigate the inhibitory effects of flavonoids on MATE1 in vitro and in vivo and to assess the effects of flavonoids on cisplatin-induced kidney injury. Thirteen flavonoids exhibited significant transport activity inhibition (>50%) on MATE1 in MATE1-MDCK cells. Among them, the six strongest flavonoid inhibitors, including irisflorentin, silymarin, isosilybin, sinensetin, tangeretin, and nobiletin, markedly increased cisplatin cytotoxicity in these cells. In cisplatin-induced in vivo renal injury models, irisflorentin, isosilybin, and sinensetin also increased serum creatinine and blood urea nitrogen levels to different degrees, especially irisflorentin, which exhibited the most potent nephrotoxicity with cisplatin. The pharmacophore model indicated that the hydrogen bond acceptors at the 3, 5, and 7 positions may play a critical role in the inhibitory effect of flavonoids on MATE1. Our findings provide helpful information for predicting the potential risks of flavonoid-containing food/herb-drug interactions and avoiding the exacerbation of drug-induced kidney injury via MATE1 mediation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    利托那韦,CYP3A4的一种出色抑制剂,最近与尼马特雷韦联合使用以形成Paxlovid,用于治疗严重的急性呼吸道综合征冠状病毒2感染。黄芩根(S.黄芩),一种传统的中草药,通常用于治疗肺部和消化道的热/炎症,它们是病毒感染的主要目标器官,含有可影响CYP3A代谢途径的黄酮。研究利托那韦通过血脑屏障(BBB)的能力及其潜在的草药-药物相互作用与等效中医临床剂量的黄芩。使用大鼠模型开发了与LCMS/MS系统耦合的多位点微透析。用黄芩提取物预处理5天,比以前的研究中使用的黄酮含量少,对利托那韦产生了重大影响,导致血液和大脑中黄酮的总浓度增加2倍。治疗还将黄酮的最大血液浓度提高了1.5倍,黄酮的最大脑浓度提高了2倍,同时对血脑屏障的转移率没有明显影响。这些实验结果表明,使用典型的中药剂量的黄芩苷足以影响代谢途径并协同增加大鼠中利托那韦的浓度。
    Ritonavir, an excellent inhibitor of CYP3A4, has recently been combined with nirmatrelvir to form Paxlovid for the treatment of severe acute respiratory syndrome coronavirus 2 infections. The root of Scutellaria baicalensis Georgi (S. baicalensis), a traditional Chinese medicinal (TCM) herb commonly used to treat heat/inflammation in the lung and digestive tracts, which are major organs targeted by viral infections, contains flavones that can influence the CYP3A metabolism pathway. To investigate the ability of ritonavir to cross the bloodbrain barrier (BBB) and its potential herb-drug interactions with an equivalent TCM clinical dose of S. baicalensis, multisite microdialysis coupled with an LCMS/MS system was developed using rat model. Pretreatment with S. baicalensis extract for 5 days, which contains less flavones than those used in previous studies, had a significant influence on ritonavir, resulting in a 2-fold increase in the total concentration of flavones in the blood and brain. Treatment also boosted the maximum blood concentration of flavones by 1.5-fold and the maximum brain concentration of flavones by 2-fold, all the while exerting no noticeable influence on the transfer ratio across the bloodbrain barrier. These experimental results demonstrated that the use of a typical traditional Chinese medicinal dose of S. baicalensis is sufficient to influence the metabolic pathway and synergistically increase the concentration of ritonavir in rats.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    根据我们先前的研究,防风(SR)可能会增强黄芪赤风汤(HQCFT)治疗脑梗死的药效学。但潜在的机制是未知的。在这里,大鼠体内药代动力学试验和体外MDCK-MDR1细胞试验用于研究SR的可能机制。其主要组成部分,以及与黄芪(AR)和芍药(PR)的相互作用。开发了一种基于超高效液相色谱-串联质谱(UPLC-MS/MS)的分析方法,用于定量微透析和运输样品中的黄芪甲苷(ASIV)和芍药苷(PAE)。使用非房室分析确定SR的药代动力学参数CCK-8测定法用于检测ASIV的细胞毒性,PAE,Cimifugin(CIM),prim-o-葡萄糖基cimifugin(POG)及其组合。此外,使用MDCK-MDR1细胞研究药物转运。进行蛋白质印迹以测量P-GP和MRP1的蛋白质表达水平。通过MDCK-MDR1细胞的免疫组织化学染色确定Claudin-5、ZO-1和F-肌动蛋白的表达。药代动力学研究表明,与黄芪赤峰汤防风(HQCFT-SR)相比,ASIV的Tmax增加了11.11%,PAE的MRT0-t和Tmax分别增加了11.19%和20%,分别,在HQCFT组中。转运研究表明,当ASIV与28μMCIM或POG共孵育时,表观渗透系数(Papp)分别增加了71.52%和50.33%,分别。PAE与120μMCIM或POG共孵育可使Papp分别增加87.62%和60.95%,分别。此外,CIM和POG显著下调P-gp和MRP1(P<0.05),抑制Claudin-5,ZO-1和F-actin的表达(P<0.05),和受影响的细胞间紧密连接(TJs)。总之,我们的研究成功地建立了一个有选择性的,灵敏且可重复的UPLC-MS/MS分析方法检测药物与药物之间的相互作用AR和PR在体内和体外,这有利于提高AR和PR的治疗效果。此外,本研究为进一步研究SR作为药物载体的用途提供了理论依据。
    Saposhnikoviae Radix (SR) may enhance the pharmacodynamics of Huangqi Chifeng Tang (HQCFT) in the treatment of cerebral infarction according to our previous research, but the underlying mechanism is unknown. Herein, an in vivo pharmacokinetic assay in rats and in vitro MDCK-MDR1 cell assays were used to investigate the possible mechanism of SR, its main components, and its interactions with Astragali Radix (AR) and Paeoniae Radix (PR). An ultrahigh-performance liquid chromatography-tandem mass spectrometry (UPLC‒MS/MS)-based analytical method for quantifying astragaloside IV (ASIV) and paeoniflorin (PAE) in microdialysis and transport samples was developed. The pharmacokinetic parameters of SR were determined using noncompartmental analyses CCK-8 assays were used to detect the cytotoxicity of ASIV, PAE, cimifugin (CIM), prim-o-glucosylcimifugin (POG) and their combinations. Moreover, drug transport was studied using MDCK-MDR1 cells. Western blotting was performed to measure the protein expression levels of P-GP and MRP1. Claudin-5, ZO-1, and F-actin expression was determined via immunohistochemical staining of MDCK-MDR1 cells. harmacokinetic studies revealed that, compared with those of Huangqi Chifeng Tang-Saposhnikoviae Radix (HQCFT-SR), the Tmax of ASIV increased by 11.11 %, and the MRT0-t and Tmax of PAE increased by 11.19 % and 20 %, respectively, in the HQCFT group. Transport studies revealed that when ASIV was coincubated with 28 μM CIM or POG, the apparent permeability coefficient (Papp) increased by 71.52 % and 50.33 %, respectively. Coincubation of PAE with 120 μM CIM or POG increased the Papp by 87.62 % and 60.95 %, respectively. Moreover, CIM and POG significantly downregulated P-gp and MRP1 (P < 0.05), inhibited the expression of Claudin-5, ZO-1, and F-actin (P < 0.05), and affected intercellular tight junctions (TJs). In conclusion, our study successfully established a selective, sensitive and reproducible UPLC‒MS/MS analytical method to detect drug‒drug interactions between SR, AR and PR in vivo and in vitro, which is beneficial for enhancing the therapeutic efficacies of AR and PR. Moreover, this study provides a theoretical basis for further research on the use of SR as a drug carrier.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:乌头的组合(川武,CW)和半夏(Thunb。)Breit(半夏,BX)在18种不相容药物(EIM)中形成一对草药对,表示BX和CW不兼容。然而,对这种不相容机制的科学理解,特别是相应的药物-药物相互作用(DDI),仍然复杂和不清楚。
    目的:本研究旨在基于药代动力学和鸡尾酒方法解释CW和BX之间的DDI和潜在的不相容性机制。
    方法:建立超高效液相色谱-串联质谱法用于药代动力学和鸡尾酒研究。为了探索BX和CW之间的DDI,在药代动力学研究中,在施用CW和BX-CW草药对提取物后,在大鼠血浆中测定10种化合物。在鸡尾酒试验中,利用5种探针底物的药代动力学参数来评估BX对细胞色素P450(CYP)同工酶的影响(氨苯砜用于CYP3A4,非那西丁用于CYP1A2,右美沙芬用于CYP2D6,甲苯磺丁胺用于CYP2C9,奥美拉唑用于CYP2C19).最后,整合了CW和BX的DDI和不相容机制,以解释EIM理论的合理性。
    结果:BX不仅增强乌头碱和苯甲酰乌头碱的吸收,而且加速了中乌头碱的代谢,苯甲酰基美松碱,松戈林,还有Fuziline.此外,BX影响CYP酶的活性,调节有毒化合物的代谢。
    结论:BX改变了CYP酶的活性,因此影响CW有毒化合物的代谢。这种不相容性机制可能与这些有毒化合物在体内的吸收增加有关。
    BACKGROUND: The combination of Aconitum carmichaelii Debx (Chuanwu, CW) and Pinellia ternata (Thunb.) Breit (Banxia, BX) forms an herbal pair within the eighteen incompatible medicaments (EIM), indicating that BX and CW are incompatible. However, the scientific understanding of this incompatibility mechanism, especially the corresponding drug-drug interaction (DDI), remains complex and unclear.
    OBJECTIVE: This study aims to explain the DDI and potential incompatibility mechanism between CW and BX based on pharmacokinetics and cocktail approach.
    METHODS: Ultraperformance liquid chromatography-tandem mass spectrometry methods were established for pharmacokinetics and cocktail studies. To explore the DDI between BX and CW, in the pharmacokinetics study, 10 compounds were determined in rat plasma after administering CW and BX-CW herbal pair extracts. In the cocktail assay, the pharmacokinetic parameters of five probe substrates were utilized to assess the influence of BX on cytochrome P450 (CYP) isoenzyme (dapsone for CYP3A4, phenacetin for CYP1A2, dextromethorphan for CYP2D6, tolbutamide for CYP2C9, and omeprazole for CYP2C19). Finally, the DDI and incompatibility mechanism of CW and BX were integrated to explain the rationality of EIM theory.
    RESULTS: BX not only enhances the absorption of aconitine and benzoylaconine but also accelerates the metabolism of mesaconitine, benzoylmesaconine, songorine, and fuziline. Moreover, BX affects the activity of CYP enzymes, which regulate the metabolism of toxic compounds.
    CONCLUSIONS: BX altered the activity of CYP enzymes, consequently affecting the metabolism of toxic compounds from CW. This incompatibility mechanism may be related to the increased absorption of these toxic compounds in vivo.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Persicariacapatata(Buch.-火腿.前D.唐)H.格罗斯,一种传统的中国药用植物,在中国通常用于治疗各种泌尿系统疾病。长久以来,头孢曲霉菌提取物(PCE)与左氧氟沙星(LVFX)联合用于治疗尿路感染(UTI)。然而,与PCE联合治疗后,小肠中LVFX的吸收和转运蛋白的表达知之甚少,制约了PCE的开发和利用。鉴于此,建立了UPLC-MS/MS法测定肠囊液样品和原位肠循环灌注液样品中LVFX的含量,以探讨PCE对LVFX离体和体内肠道吸收特性的影响。为了进一步评估LVFX和PCE之间的相互作用,西方印迹,免疫组织化学,和RT-qPCR用于确定药物转运蛋白的表达水平(OATP1A2,P-gp,BCRP,和MRP2)参与与PCE联合治疗后LVFX的肠道吸收。使用外翻肠囊模型,PCE治疗组各肠段LVFX的吸收率常数(Ka)和累积药物吸收(Q)均显著低于对照组。在2小时时,Ka在结肠段下降最多(从0.088到0.016µg/h·cm2),在2小时时,Q在十二指肠中下降最多(从213.29µg降至33.92µg)。使用肠循环灌注模型,当PCE和LVFX联合使用时,LVFX在小肠中的Ka值和百分比吸收率(A)显着降低。这些结果表明,PCE对大鼠小肠(离体和体内肠段)中LVFX的吸收具有很强的抑制作用。此外,PCE增加外排转运蛋白的蛋白和mRNA表达水平(P-gp,BCRP,和MRP2)并显着降低摄取转运蛋白OATP1A2的表达。效果随着PCE浓度的增加而增加。这些发现表明PCE改变了左氧氟沙星的吸收特性,可能通过影响小肠中转运蛋白的表达。除了揭示PCE和LVFX之间的草药-药物相互作用(HDI),这些结果为进一步研究其临床疗效和作用机制提供了依据。
    Persicaria capitata (Buch.-Ham. ex D. Don) H. Gross, a traditional Chinese medicinal plant, is often used to treat various urologic disorders in China. P. capitata extracts (PCE) have been used in combination with levofloxacin (LVFX) to treat urinary tract infections (UTIs) for a long time. However, little is known about the absorption of LVFX and transporter expression in the intestine after combined treatment with PCE, restricting the development and utilization of PCE. In view of this, a UPLC-MS/MS method was established for the determination of LVFX in intestinal sac fluid samples and in situ intestinal circulation perfusate samples to explore the effect of PCE on the intestinal absorption characteristics of LVFX ex vivo and in vivo. To further evaluate the interaction between LVFX and PCE, western blotting, immunohistochemistry, and RT-qPCR were utilized to determine the expression levels of drug transporters (OATP1A2, P-gp, BCRP, and MRP2) involved in the intestinal absorption of LVFX after combined treatment with PCE. Using the everted intestinal sac model, the absorption rate constant (Ka) and cumulative drug absorption (Q) of LVFX in each intestinal segment were significantly lower in groups treated with PCE than in the control group. Ka at 2 h decreased most in the colon segment (from 0.088 to 0.016 µg/h·cm2), and Q at 2 h decreased most in the duodenum (from 213.29 to 33.92 µg). Using the intestinal circulation perfusion model, the Ka value and percentage absorption rate (A) of LVFX in the small intestine decreased significantly when PCE and LVFX were used in combination. These results showed that PCE had a strong inhibitory effect on the absorption of LVFX in the rat small intestine (ex vivo and in vivo intestinal segments). In addition, PCE increased the protein and mRNA expression levels of efflux transporters (P-gp, BCRP, and MRP2) and decreased the expression of the uptake transporter OATP1A2 significantly. The effects increased as the PCE concentration increased. These findings indicated that PCE changed the absorption characteristics of levofloxacin, possibly by affecting the expression of transporters in the small intestine. In addition to revealing a herb-drug interaction (HDI) between PCE and LVFX, these results provide a basis for further studies of their clinical efficacy and mechanism of action.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Editorial
    植物已经进化出复杂的免疫系统来保护自己免受潜在病原体的侵害[。..].
    Plants have evolved an intricate immune system to protect themselves from potential pathogens [...].
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    重金属污染威胁着植物的生长发育和生态稳定。这里,我们综合了重金属胁迫下植物与其微生物共生体之间相互作用的最新研究,强调微生物增强植物耐受性和恢复力的机制。几个关键策略,如生物利用度改变,螯合,排毒,诱导的全身耐受,水平基因转移,甲基化和去甲基化,被检查,以及控制这些植物-微生物相互作用的遗传和分子基础。然而,植物-微生物相互作用的复杂性,再加上我们对相关机制的了解有限,在实际应用中提出了挑战。因此,这篇综述强调了更详细了解植物和微生物如何相互作用的必要性,以及使用不同科学领域的综合方法来最大限度地发挥这些微生物过程的益处的重要性。通过提高我们对重金属代谢中植物-微生物协同作用的认识,我们可以制定更有效的生物修复策略来对抗重金属对土壤的污染。
    Heavy metal pollution threatens plant growth and development as well as ecological stability. Here, we synthesize current research on the interplay between plants and their microbial symbionts under heavy metal stress, highlighting the mechanisms employed by microbes to enhance plant tolerance and resilience. Several key strategies such as bioavailability alteration, chelation, detoxification, induced systemic tolerance, horizontal gene transfer, and methylation and demethylation, are examined, alongside the genetic and molecular basis governing these plant-microbe interactions. However, the complexity of plant-microbe interactions, coupled with our limited understanding of the associated mechanisms, presents challenges in their practical application. Thus, this review underscores the necessity of a more detailed understanding of how plants and microbes interact and the importance of using a combined approach from different scientific fields to maximize the benefits of these microbial processes. By advancing our knowledge of plant-microbe synergies in the metabolism of heavy metals, we can develop more effective bioremediation strategies to combat the contamination of soil by heavy metals.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号